Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Global tuberculosis targets and milestones set for 2016-2035: definition and rationale.

Floyd K, Glaziou P, Houben RMGJ, Sumner T, White RG, Raviglione M.

Int J Tuberc Lung Dis. 2018 Jul 1;22(7):723-730. doi: 10.5588/ijtld.17.0835.

2.

Trends in tuberculosis in the UK.

Glaziou P, Floyd K, Raviglione M.

Thorax. 2018 Aug;73(8):702-703. doi: 10.1136/thoraxjnl-2018-211537. Epub 2018 Apr 19. No abstract available.

3.

The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era.

Floyd K, Glaziou P, Zumla A, Raviglione M.

Lancet Respir Med. 2018 Apr;6(4):299-314. doi: 10.1016/S2213-2600(18)30057-2. Review.

PMID:
29595511
4.

The impact of social protection and poverty elimination on global tuberculosis incidence: a statistical modelling analysis of Sustainable Development Goal 1.

Carter DJ, Glaziou P, Lönnroth K, Siroka A, Floyd K, Weil D, Raviglione M, Houben RMGJ, Boccia D.

Lancet Glob Health. 2018 May;6(5):e514-e522. doi: 10.1016/S2214-109X(18)30195-5. Epub 2018 Mar 23.

5.

Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study.

Zignol M, Cabibbe AM, Dean AS, Glaziou P, Alikhanova N, Ama C, Andres S, Barbova A, Borbe-Reyes A, Chin DP, Cirillo DM, Colvin C, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Hussain A, Ismail N, Kamal SMM, Khanzada FM, Kimerling M, Kohl TA, Mansjö M, Miotto P, Mukadi YD, Mvusi L, Niemann S, Omar SV, Rigouts L, Schito M, Sela I, Seyfaddinova M, Skenders G, Skrahina A, Tahseen S, Wells WA, Zhurilo A, Weyer K, Floyd K, Raviglione MC.

Lancet Infect Dis. 2018 Jun;18(6):675-683. doi: 10.1016/S1473-3099(18)30073-2. Epub 2018 Mar 21. Erratum in: Lancet Infect Dis. 2018 Mar 27;:.

6.

A roadmap for zoonotic tuberculosis: a One Health approach to ending tuberculosis.

Dean AS, Forcella S, Olea-Popelka F, Idrissi AE, Glaziou P, Benyahia A, Mumford E, Erlacher-Vindel E, Gifford G, Lubroth J, Raviglione M, Fujiwara P.

Lancet Infect Dis. 2018 Feb;18(2):137-138. doi: 10.1016/S1473-3099(18)30013-6. No abstract available.

PMID:
29412954
7.

End TB strategy: the need to reduce risk inequalities.

Gomes MG, Barreto ML, Glaziou P, Medley GF, Rodrigues LC, Wallinga J, Squire SB.

BMC Infect Dis. 2016 Mar 22;16:132. doi: 10.1186/s12879-016-1464-8.

8.

TB deaths rank alongside HIV deaths as top infectious killer.

Glaziou P, Floyd K, Weil D, Raviglione M.

Int J Tuberc Lung Dis. 2016 Feb;20(2):143-4. doi: 10.5588/ijtld.15.0985. No abstract available.

PMID:
26792460
9.

National tuberculosis prevalence surveys in Asia, 1990-2012: an overview of results and lessons learned.

Onozaki I, Law I, Sismanidis C, Zignol M, Glaziou P, Floyd K.

Trop Med Int Health. 2015 Sep;20(9):1128-1145. doi: 10.1111/tmi.12534. Epub 2015 Jun 7.

10.

WHO's new end TB strategy.

Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, Falzon D, Floyd K, Gargioni G, Getahun H, Gilpin C, Glaziou P, Grzemska M, Mirzayev F, Nakatani H, Raviglione M; for WHO's Global TB Programme.

Lancet. 2015 May 2;385(9979):1799-1801. doi: 10.1016/S0140-6736(15)60570-0. Epub 2015 Mar 24. No abstract available.

PMID:
25814376
11.

Towards tuberculosis elimination: an action framework for low-incidence countries.

Lönnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, Douglas P, Falzon D, Gaudreau MA, Goletti D, González Ochoa ER, LoBue P, Matteelli A, Njoo H, Solovic I, Story A, Tayeb T, van der Werf MJ, Weil D, Zellweger JP, Abdel Aziz M, Al Lawati MR, Aliberti S, Arrazola de Oñate W, Barreira D, Bhatia V, Blasi F, Bloom A, Bruchfeld J, Castelli F, Centis R, Chemtob D, Cirillo DM, Colorado A, Dadu A, Dahle UR, De Paoli L, Dias HM, Duarte R, Fattorini L, Gaga M, Getahun H, Glaziou P, Goguadze L, Del Granado M, Haas W, Järvinen A, Kwon GY, Mosca D, Nahid P, Nishikiori N, Noguer I, O'Donnell J, Pace-Asciak A, Pompa MG, Popescu GG, Robalo Cordeiro C, Rønning K, Ruhwald M, Sculier JP, Simunović A, Smith-Palmer A, Sotgiu G, Sulis G, Torres-Duque CA, Umeki K, Uplekar M, van Weezenbeek C, Vasankari T, Vitillo RJ, Voniatis C, Wanlin M, Raviglione MC.

Eur Respir J. 2015 Apr;45(4):928-52. doi: 10.1183/09031936.00214014. Review.

12.

Using the TIME model in Spectrum to estimate tuberculosis-HIV incidence and mortality.

Pretorius C, Glaziou P, Dodd PJ, White R, Houben R.

AIDS. 2014 Nov;28 Suppl 4:S477-87. doi: 10.1097/QAD.0000000000000484.

13.

Global epidemiology of tuberculosis.

Glaziou P, Sismanidis C, Floyd K, Raviglione M.

Cold Spring Harb Perspect Med. 2014 Oct 30;5(2):a017798. doi: 10.1101/cshperspect.a017798. Review.

14.

The burden of tuberculosis disease in children.

Sismanidis C, Glaziou P, Law I, Floyd K.

Lancet. 2014 Oct 11;384(9951):1343. doi: 10.1016/S0140-6736(14)61810-9. No abstract available.

PMID:
25307836
15.

Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries.

Knight GM, Griffiths UK, Sumner T, Laurence YV, Gheorghe A, Vassall A, Glaziou P, White RG.

Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15520-5. doi: 10.1073/pnas.1404386111. Epub 2014 Oct 6.

16.

Beyond UHC: monitoring health and social protection coverage in the context of tuberculosis care and prevention.

Lönnroth K, Glaziou P, Weil D, Floyd K, Uplekar M, Raviglione M.

PLoS Med. 2014 Sep 22;11(9):e1001693. doi: 10.1371/journal.pmed.1001693. eCollection 2014 Sep. Review.

17.

Analysis of tuberculosis prevalence surveys: new guidance on best-practice methods.

Floyd S, Sismanidis C, Yamada N, Daniel R, Lagahid J, Mecatti F, Vianzon R, Bloss E, Tiemersma E, Onozaki I, Glaziou P, Floyd K.

Emerg Themes Epidemiol. 2013 Sep 28;10(1):10. doi: 10.1186/1742-7622-10-10.

18.

Moving the goalposts for tuberculosis targets in Africa.

Floyd K, Glaziou P, Raviglione M.

Lancet. 2013 Jul 6;382(9886):27. doi: 10.1016/S0140-6736(13)61526-3. No abstract available.

PMID:
23830339
19.

Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts.

Marais BJ, Lönnroth K, Lawn SD, Migliori GB, Mwaba P, Glaziou P, Bates M, Colagiuri R, Zijenah L, Swaminathan S, Memish ZA, Pletschette M, Hoelscher M, Abubakar I, Hasan R, Zafar A, Pantaleo G, Craig G, Kim P, Maeurer M, Schito M, Zumla A.

Lancet Infect Dis. 2013 May;13(5):436-48. doi: 10.1016/S1473-3099(13)70015-X. Epub 2013 Mar 24. Review.

20.

Estimating tuberculosis burden and reporting in resource-limited countries: a capture-recapture study in Iraq.

Huseynova S, Hashim DS, Tbena MR, Harris R, Bassili A, Abubakar I, Glaziou P, Floyd K, van Hest NA.

Int J Tuberc Lung Dis. 2013 Apr;17(4):462-7. doi: 10.5588/ijtld.12.0209.

PMID:
23485379
21.

Estimating the tuberculosis burden in resource-limited countries: a capture-recapture study in Yemen.

Bassili A, Al-Hammadi A, Al-Absi A, Glaziou P, Seita A, Abubakar I, Bierrenbach AL, van Hest NA.

Int J Tuberc Lung Dis. 2013 Apr;17(4):456-61. doi: 10.5588/ijtld.11.0483. Erratum in: Int J Tuberc Lung Dis. 2014 Jun;18(6):754.

PMID:
23485378
22.

Global epidemiology of tuberculosis.

Glaziou P, Falzon D, Floyd K, Raviglione M.

Semin Respir Crit Care Med. 2013 Feb;34(1):3-16. doi: 10.1055/s-0032-1333467. Epub 2013 Mar 4. Review.

23.

Prospects for tuberculosis elimination.

Dye C, Glaziou P, Floyd K, Raviglione M.

Annu Rev Public Health. 2013;34:271-86. doi: 10.1146/annurev-publhealth-031912-114431. Epub 2012 Dec 14. Review.

PMID:
23244049
24.

Multidrug-resistant tuberculosis in children: evidence from global surveillance.

Zignol M, Sismanidis C, Falzon D, Glaziou P, Dara M, Floyd K.

Eur Respir J. 2013 Sep;42(3):701-7. doi: 10.1183/09031936.00175812. Epub 2012 Dec 6.

25.

WHO guidance on electronic systems to manage data for tuberculosis care and control.

Timimi H, Falzon D, Glaziou P, Sismanidis C, Floyd K.

J Am Med Inform Assoc. 2012 Nov-Dec;19(6):939-41. doi: 10.1136/amiajnl-2011-000755. Epub 2012 Jun 22.

26.

Implementing the global plan to stop TB, 2011-2015--optimizing allocations and the Global Fund's contribution: a scenario projections study.

Korenromp EL, Glaziou P, Fitzpatrick C, Floyd K, Hosseini M, Raviglione M, Atun R, Williams B.

PLoS One. 2012;7(6):e38816. doi: 10.1371/journal.pone.0038816. Epub 2012 Jun 18.

27.

Global tuberculosis control: lessons learnt and future prospects.

Lienhardt C, Glaziou P, Uplekar M, Lönnroth K, Getahun H, Raviglione M.

Nat Rev Microbiol. 2012 May 14;10(6):407-16. doi: 10.1038/nrmicro2797. Review.

PMID:
22580364
28.

Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010.

Zignol M, van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, Raviglione M.

Bull World Health Organ. 2012 Feb 1;90(2):111-119D. doi: 10.2471/BLT.11.092585. Epub 2011 Nov 7.

29.

Lives saved by tuberculosis control and prospects for achieving the 2015 global target for reducing tuberculosis mortality.

Glaziou P, Floyd K, Korenromp EL, Sismanidis C, Bierrenbach AL, Williams BG, Atun R, Raviglione M.

Bull World Health Organ. 2011 Aug 1;89(8):573-82. doi: 10.2471/BLT.11.087510. Epub 2011 May 31.

30.

Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?

Loeliger A, Suthar AB, Ripin D, Glaziou P, O'Brien M, Renaud-Thery F, Crowley S, Williams B, Ridzon R, Granich R, Gilks C.

Int J Tuberc Lung Dis. 2012 Jan;16(1):6-15. doi: 10.5588/ijtld.10.0626. Epub 2011 Aug 3. Review.

PMID:
21819645
31.

Assessing tuberculosis case fatality ratio: a meta-analysis.

Straetemans M, Glaziou P, Bierrenbach AL, Sismanidis C, van der Werf MJ.

PLoS One. 2011;6(6):e20755. doi: 10.1371/journal.pone.0020755. Epub 2011 Jun 27. Review.

32.

Tuberculosis mortality in HIV-infected individuals: a cross-national systematic assessment.

Au-Yeung C, Kanters S, Ding E, Glaziou P, Anema A, Cooper CL, Montaner JS, Hogg RS, Mills EJ.

Clin Epidemiol. 2011 Jan 19;3:21-9. doi: 10.2147/CLEP.S15574.

33.

The effect of tuberculosis on mortality in HIV positive people: a meta-analysis.

Straetemans M, Bierrenbach AL, Nagelkerke N, Glaziou P, van der Werf MJ.

PLoS One. 2010 Dec 30;5(12):e15241. doi: 10.1371/journal.pone.0015241.

34.

Antiretroviral therapy for tuberculosis control in nine African countries.

Williams BG, Granich R, De Cock KM, Glaziou P, Sharma A, Dye C.

Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19485-9. doi: 10.1073/pnas.1005660107. Epub 2010 Oct 25.

35.

Tuberculosis control and elimination 2010-50: cure, care, and social development.

Lönnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, Raviglione MC.

Lancet. 2010 May 22;375(9728):1814-29. doi: 10.1016/S0140-6736(10)60483-7.

PMID:
20488524
36.

Estimating tuberculosis case detection rate in resource-limited countries: a capture-recapture study in Egypt.

Bassili A, Grant AD, El-Mohgazy E, Galal A, Glaziou P, Seita A, Abubakar I, Bierrenbach AL, Crofts JP, van Hest NA.

Int J Tuberc Lung Dis. 2010 Jun;14(6):727-32.

PMID:
20487611
37.

Global burden and epidemiology of tuberculosis.

Glaziou P, Floyd K, Raviglione M.

Clin Chest Med. 2009 Dec;30(4):621-36, vii. doi: 10.1016/j.ccm.2009.08.017. Review.

PMID:
19925958
38.

Protecting patients' rights, ensuring safety and quality assurance in tuberculosis prevalence surveys.

Chiang CY, Glaziou P, Enarson DA, Cobelens F, Lew WJ.

Int J Tuberc Lung Dis. 2009 Jan;13(1):27-31.

PMID:
19105875
39.

Tuberculosis prevalence surveys: rationale and cost.

Glaziou P, van der Werf MJ, Onozaki I, Dye C, Borgdorff MW, Chiang CY, Cobelens F, Enarson DA, Gopi PG, Holtz TH, Kim SJ, van Leth F, Lew WJ, Lonnroth K, van Maaren P, Narayanan PR, Williams B.

Int J Tuberc Lung Dis. 2008 Sep;12(9):1003-8.

PMID:
18713496
40.

Tuberculosis prevalence surveys: an educational series.

Glaziou P.

Int J Tuberc Lung Dis. 2008 Sep;12(9):985. No abstract available.

PMID:
18713492
41.

[Serological study carried out in Cambodia during a tetanus vaccination in adults].

Schlumberger M, Yvonnet B, Que HV, Chhem DB, Saliou P, Le Tu TC, Glaziou P.

Bull Soc Pathol Exot. 2008 Feb;101(1):36-42. French.

PMID:
18432006
42.

Measuring tuberculosis burden, trends, and the impact of control programmes.

Dye C, Bassili A, Bierrenbach AL, Broekmans JF, Chadha VK, Glaziou P, Gopi PG, Hosseini M, Kim SJ, Manissero D, Onozaki I, Rieder HL, Scheele S, van Leth F, van der Werf M, Williams BG.

Lancet Infect Dis. 2008 Apr;8(4):233-43. doi: 10.1016/S1473-3099(07)70291-8. Epub 2008 Jan 16. Review.

PMID:
18201929
43.

Reverse transcriptase mutations in Cambodian CRF01_AE isolates after antiretroviral prophylaxis against HIV Type 1 perinatal transmission.

Ly N, Phoung V, Min DC, Srey C, Kruy LS, Koum K, Chhum V, Glaziou P, Fleury HJ, Reynes JM.

AIDS Res Hum Retroviruses. 2007 Dec;23(12):1563-8.

PMID:
18160014
44.

Reaching the global tuberculosis control targets in the Western Pacific Region.

van Maaren P, Tomas B, Glaziou P, Kasai T, Ahn D.

Bull World Health Organ. 2007 May;85(5):360-3.

45.

Characterization of mutations in HIV type 1 isolates from 144 Cambodian recently infected patients and pregnant women naive to antiretroviral drugs.

Ly N, Recordon-Pinson P, Phoung V, Srey C, Kruy LS, Koum K, Chhum V, Glaziou P, Fleury HJ, Reynes JM.

AIDS Res Hum Retroviruses. 2005 Nov;21(11):971-6.

PMID:
16386116
46.

Secondary dengue virus type 4 infections in Vietnam.

Buchy P, Vo VL, Bui KT, Trinh TX, Glaziou P, Le TT, Le VL, Bui TC.

Southeast Asian J Trop Med Public Health. 2005 Jan;36(1):178-85.

PMID:
15906664
47.
48.
49.

A community-based tuberculosis program in Cambodia.

Thim S, Sath S, Sina M, Tsai EY, Delgado JC, Shapiro AE, Barry CE 3rd, Glaziou P, Goldfeld AE.

JAMA. 2004 Aug 4;292(5):566-8. No abstract available.

PMID:
15292081
50.

HIV, STIs, and sexual behaviors among men who have sex with men in Phnom Penh, Cambodia.

Girault P, Saidel T, Song N, de Lind Van Wijngaarden JW, Dallabetta G, Stuer F, Mills S, Or V, Grosjean P, Glaziou P, Pisani E.

AIDS Educ Prev. 2004 Feb;16(1):31-44.

PMID:
15058709

Supplemental Content

Loading ...
Support Center